Literature DB >> 34013383

Clinicopathologic and molecular characterization of melanomas mutated for CTNNB1 and MAPK.

Bénédicte Oulès1,2,3, Samia Mourah4,5, Barouyr Baroudjian1, Fanélie Jouenne4,5, Julie Delyon1,5, Baptiste Louveau4,5, Aurélia Gruber4,5, Céleste Lebbé1,5, Maxime Battistella6,7.   

Abstract

Wnt/β-catenin signaling plays crucial roles in melanocyte biology and may be implicated in melanoma progression. In this study, we retrospectively examined a real-life cohort of melanomas mutated for β-catenin (CTNNB1), in association or not with a MAPK mutation (of BRAF or NRAS), and analyzed their clinical, histopathological, and molecular characteristics. Our results indicate that, regardless of the presence of a concurrent MAPK mutation, CTNNB1mut cutaneous primary melanomas display more proliferative hallmarks (increased Breslow thickness, mitotic index, and ulceration) than their CTNNB1 wild-type counterparts. Accordingly, they often progress to the metastatic stage. Furthermore, concurrent CTNNB1 and MAPK mutations do not necessarily confer a deep penetrating nevi phenotype. Altogether, this study provides evidence that CTNNB1 mutations in melanomas are associated with specific clinical and pathological features.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  BRAF mutation; CTNNB1 mutation; Cutaneous melanoma; Deep penetrating nevus; NRAS mutation

Mesh:

Substances:

Year:  2021        PMID: 34013383     DOI: 10.1007/s00428-021-03119-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  15 in total

1.  Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma.

Authors:  Travis L Biechele; Rima M Kulikauskas; Rachel A Toroni; Olivia M Lucero; Reyna D Swift; Richard G James; Nick C Robin; David W Dawson; Randall T Moon; Andy J Chien
Journal:  Sci Signal       Date:  2012-01-10       Impact factor: 8.192

2.  Neural crest-directed gene transfer demonstrates Wnt1 role in melanocyte expansion and differentiation during mouse development.

Authors:  K J Dunn; B O Williams; Y Li; W J Pavan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

3.  β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.

Authors:  William E Damsky; David P Curley; Manjula Santhanakrishnan; Lara E Rosenbaum; James T Platt; Bonnie E Gould Rothberg; Makoto M Taketo; David Dankort; David L Rimm; Martin McMahon; Marcus Bosenberg
Journal:  Cancer Cell       Date:  2011-12-13       Impact factor: 31.743

4.  Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model.

Authors:  Andy J Chien; Erin C Moore; Anke S Lonsdorf; Rima M Kulikauskas; Bonnie Gould Rothberg; Aaron J Berger; Michael B Major; Sam T Hwang; David L Rimm; Randall T Moon
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-14       Impact factor: 11.205

5.  Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development.

Authors:  Véronique Delmas; Friedrich Beermann; Silvia Martinozzi; Suzanne Carreira; Julien Ackermann; Mayuko Kumasaka; Laurence Denat; Jane Goodall; Flavie Luciani; Amaya Viros; Nese Demirkan; Boris C Bastian; Colin R Goding; Lionel Larue
Journal:  Genes Dev       Date:  2007-11-15       Impact factor: 11.361

Review 6.  Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities.

Authors:  Roel Nusse; Hans Clevers
Journal:  Cell       Date:  2017-06-01       Impact factor: 41.582

7.  Lineage-specific requirements of beta-catenin in neural crest development.

Authors:  Lisette Hari; Véronique Brault; Maurice Kléber; Hye-Youn Lee; Fabian Ille; Rainer Leimeroth; Christian Paratore; Ueli Suter; Rolf Kemler; Lukas Sommer
Journal:  J Cell Biol       Date:  2002-12-09       Impact factor: 10.539

Review 8.  Exon 3 mutations of CTNNB1 drive tumorigenesis: a review.

Authors:  Chao Gao; Yingmei Wang; Russell Broaddus; Longhao Sun; Fengxia Xue; Wei Zhang
Journal:  Oncotarget       Date:  2017-11-24

Review 9.  Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches.

Authors:  Giuseppe Palmieri; Maria Colombino; Milena Casula; Antonella Manca; Mario Mandalà; Antonio Cossu
Journal:  Curr Oncol Rep       Date:  2018-09-14       Impact factor: 5.075

10.  Patterns of genomic evolution in advanced melanoma.

Authors:  E Birkeland; S Zhang; D Poduval; J Geisler; S Nakken; D Vodak; L A Meza-Zepeda; E Hovig; O Myklebost; S Knappskog; P E Lønning
Journal:  Nat Commun       Date:  2018-07-10       Impact factor: 14.919

View more
  1 in total

1.  Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions.

Authors:  Anne Zaremba; Philipp Jansen; Rajmohan Murali; Anand Mayakonda; Anna Riedel; Dieter Krahl; Hans Burkhardt; Stefan John; Cyrill Géraud; Manuel Philip; Julia Kretz; Inga Möller; Nadine Stadtler; Antje Sucker; Annette Paschen; Selma Ugurel; Lisa Zimmer; Elisabeth Livingstone; Susanne Horn; Christoph Plass; Dirk Schadendorf; Eva Hadaschik; Pavlo Lutsik; Klaus Griewank
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.